Autopsy report · NCT04785924

Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Lack of enrollment”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 4
Sponsor: Wake Forest University Health Sciences
Sponsor type: University, hospital or other
Conditions: Carbapenem-Resistant Enterobacteriaceae Infection; KPC; Gram-Negative Bacterial Infections; Antibiotic Resistant Infection
Interventions: Imipenem+Relebactam
Participants: 0
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.